Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine nasal spray for rapid reduction of depressive symptoms in adults with major depressive disorder and imminent suicide risk
2016-003990-17Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Esketamine plus standard of care with Placebo plus standard of care (2 arms). Primary endpoint: Change from baseline in depressive symptoms. Started Apr 2017; status: completed.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2016-003990-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003990-17.